Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Lauren N Scott, William Wesson, Pilar Thangwaritorn, Raeef L Rahman, Forat Lutfi, Marc Hoffmann, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Sunil Abhyankar, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 389.

https://doi.org/10.1182/blood-2024-205983

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Joseph G Bennett, Kamen Kossow, Leah Diebolt, Nicole Twardowski, Jianzheng Wu, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Brian Hess, James A Davis, Al-Ola Abdallah, Nausheen Ahmed, Joseph P. McGuirk, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 6556.

https://doi.org/10.1182/blood-2024-201728

Published: 2024

Journal Articles

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Marc Hoffmann, Theodoros Vassilakopoulos, Javier Munoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Alejandro Berkovits, Tai-Chung Huang, Akshay Sudhindra, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Grzegorz S. Nowakowski

Blood (2024) 144 (Supplement 1): 1742.2.

https://doi.org/10.1182/blood-2024-203185

Published: 2024

Journal Articles

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Raphael Steiner, Allison M. Bock, Alex F. Herrera, Omer Zulfa, Marc Hoffmann, Sami Ibrahimi, Natalie Galanina, Hun Ju Lee, Michael Green, Ruitao Lin, Chelsea C. Pinnix, Alison Moskowitz, Joachim Yahalom, Dai Chihara

Blood (2024) 144 (Supplement 1): 4434.2.

https://doi.org/10.1182/blood-2024-202516

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Raeef L Rahman, Jianzheng Wu, Lauren N Scott, William Wesson, Razan Mansour, Aung M. Tun, Marc Hoffmann, Al-Ola Abdallah, Dinesh Pal Mudaranthakam, Joseph P. McGuirk, Nausheen Ahmed, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7099.

https://doi.org/10.1182/blood-2024-205978

Published: 2024

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Deborah M. Stephens, Chris Stewart, Liza Avruch, Catherine C Coombs, Alexey Danilov, Brian T. Hill, Mazyar Shadman, Alina S. Gerrie, Christopher E. Jensen, Marc Hoffmann, Allison M. Winter, Daniel A. Ermann, Paul M Barr, Susan M. O'Brien, Brian Koffman, John C. Byrd

Blood (2024) 144 (Supplement 1): 7743.

https://doi.org/10.1182/blood-2024-193298

Published: 2024

Journal Articles

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Arnaud Amzallag, Tara Basavanhally, Jason R. Westin, Marc Hoffmann, Theodoros P. Vassilakopoulos, Javier Munoz, Grzegorz S. Nowakowski, Floriane Boucaud, Matt Stokes, Akshay Sudhindra, Anita K. Gandhi, Mark Kaplan

Blood (2024) 144 (Supplement 1): 579.

https://doi.org/10.1182/blood-2024-203135

Published: 2024

Journal Articles

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Hannah Katz, Lauren N Scott, Pilar Thangwaritorn, Jianzheng Wu, William Wesson, Dinesh Pal Mudaranthakam, Shaun DeJarnette, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi, Sunil Abhyankar, Leyla O. Shune, Muhammad Umair Mushtaq, Anurag Singh, Haitham Abdelhakim, Joseph P. McGuirk, Muhammad Mahdi Nashatizadeh, Liz Muenks, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5030.

https://doi.org/10.1182/blood-2024-199312

Published: 2024

Journal Articles

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Sara Leidy, Jordan Snyder, James A Davis, William Wesson, Brian Hess, Ryan Jacobs, Madalyn Edmonds, Nausheen Ahmed, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2024-199658

Published: 2024

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 557–560.

https://doi.org/10.1182/blood-2022-159123

Published: 2022

Journal Articles

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma

William Wesson, Maggie Nelson, Muhammad Mushtaq, Rajat Bansal, Robert Kribs, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Al-Ola Abdallah, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12757–12759.

https://doi.org/10.1182/blood-2022-162433

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 846–849.

https://doi.org/10.1182/blood-2022-157058

Published: 2022

Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 4127–4132.

https://doi.org/10.1182/blood-2022-159035

Published: 2022

Journal Articles

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

William Wesson, Wei Cui, Muhammad Mushtaq, Rajat Bansal, Anurag K. Singh, Marc Hoffmann, Aung M Tun, Ramesh Balusu, Haitham Abdelhakim, Sunil H Abhyankar, Joseph P. McGuirk, Leyla O. Shune, Al-Ola Abdallah, Nausheen Ahmed

Blood (2022) 140 (Supplement 1): 12781–12783.

https://doi.org/10.1182/blood-2022-160437

Published: 2022

Journal Articles

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Jason Westin, Alejandro Martín García-Sancho, Marc Hoffmann, Theodoros P. Vassilakopoulos, Su-Peng Yeh, Argyrios Gkasiamis, Poliana Patah, Arpankumar Patel, Ju Li, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 9475–9477.

https://doi.org/10.1182/blood-2022-162774

Published: 2022

NARROW

Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Chimeric Antigen T-Cell (CAR-T) Therapy Versus Autologous Stem Cell Transplantation (ASCT) in Secondary Central Nervous System Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

B- Cell Maturation Antigen (BCMA) Re-Emergence and Relapse Patterns Post-BCMA-Chimeric Antigen Receptor T Cell (CAR-T ) Therapy for Multiple Myeloma

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only